Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA-026 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMA-026 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: 1. Healthy men and women 18 to 60 yrs with mild allergic asthma 2. only asthma med is short-acting bronchodilator used not more than twice weekly 3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction Exclusion Criteria: 1. Upper res...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
IMA-026 is an investigational small molecule being developed by Pfizer, Inc. (ticker PFE) as a potential treatment for asthma. It has been studied in a Phase 1 clinical trial and is not yet approved for any indication. It belongs to the respiratory therapeutic area.
IMA-026 is being evaluated for the treatment of asthma, specifically in patients with mild asthma. A Phase 1 study assessed its effect on allergen-induced late asthma response. The drug remains investigational and has not been approved for clinical use in asthma or any other condition.
IMA-026 is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the clinical research evaluating the compound in asthma. No other developer or partnership for IMA-026 is disclosed.
IMA-026 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not received FDA approval for any indication.
IMA-026 has been studied in one completed Phase 1 trial, NCT00725582, titled "Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma." The trial enrolled 24 participants, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.